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home parenteral nutrition, a NOD2 mutation and
tuberculous lymphadenitis
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Background: Mutations in the NOD2 gene are a significant risk factor to acquire intestinal failure requiring home
parenteral nutrition. Tuberculous lymphadenitis is the main manifestation of extrapulmonary tuberculosis. Defects
in the innate immunity, including NOD2 mutations, may increase the risk for acquiring infections caused by
M. tuberculosis. An association of intestinal failure, mutations in the NOD2 gene and tuberculous lymphadenitis
has not been described before.
Case presentation: We report of two patients with intestinal failure secondary to mesenteric ischemia. Both
patients presented with fever and weight loss while receiving long term home parenteral nutrition. Both of them
were found to have mutations in the NOD2 gene. Catheter related infections were ruled out. FDG-PET-CT scans
initially obtained in search for another infectious focus that would explain the symptoms unexpectedly showed
high FDG uptake in mediastinal lymph nodes. Direct or indirect evidence proved or was highly suggestive for
tuberculous lymphadenitis. Intravenous tuberculostatic therapy was started and led to a reversal of symptoms and
to resolution of the lesions by FDG-PET-CT.
Conclusion: Mutations in the NOD2 gene may put patients both at an increased risk for acquiring M. tuberculosis
infections as well as at an increased risk of intestinal failure after extensive intestinal resection. Thus we suggest to
specifically include reactivated and opportunistic infections in the differential diagnosis of suspected catheter
related infection in patients with intestinal failure who carry mutations in their NOD2 gene.
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Tuberculous lymphadenitis is the most frequent site of
extrapulmonary tuberculosis. About 20% of all TBC cases
in the US are extrapulmonary. From this group, about
40% are tuberculous lymphadentis [1]. Detection of M. tu-
berculosis is mainly via the innate immune system by
extracellular or intracellular pattern recognition receptors
(PRR) such as toll-like receptors (TLR) and nucleotide-
binding oligomerization domain receptors (NOD) [2-4].
Mutations in specific TLR genes were found to be associ-
ated with susceptibility to TBC [5,6].
Clinical relevance of mutations in the NOD2 gene
arises from their association with Crohn’s disease [7-10].* Correspondence: georg.lamprecht@med.uni-rostock.de
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unless otherwise stated.In 2001, a link between mutations in the NOD2 gene
and Crohn’s disease was first established independently
by two different groups [11,12]. However, the exact func-
tion of NOD2 is still under debate [13]. Besides Crohn’s
disease, other disease entities seem to be related to mu-
tations in the NOD2 gene like GvHD [14-16], acute
septicemia [17], spontaneous bacterial peritonitis in liver
cirrhosis [18,19] and worsened outcome after intestinal
transplantation [20]. Mutations in the NOD2 gene and
an increased susceptibility for infectious diseases have
been reported in the literature [21]. NOD2 is also
thought to be an important receptor in recognizing M.
tuberculosis, because on the one hand both the receptor
and the pathogen are intracellular and on the other hand
the cell wall of M. tuberculosis contains peptidoglycan,
which is one of the ligands of NOD2 [22]. However, the
role of NOD2 in tuberculous lymphadenitis has not beenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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new SNP in the NOD2 gene as a possible risk factor for
pulmonary tuberculosis in the Chinese Han population
[23]. In another study it was reported that genes in the
NOD2 signaling pathway are associated with susceptibility
to infections withMycobacterium leprae in China [24].
Short bowel syndrome (SBS) and intestinal failure re-
quiring long term home parenteral nutrition (HPN) are
rare heterogeneous clinical conditions in which extensive
parts of the intestine have been removed surgically. The
main causes of short bowel syndrome in adults are
Crohn’s disease, intestinal ischemia, volvulus, ileus, des-
moid tumors and trauma [25]. Recently we have de-
scribed an increased frequency of NOD2 mutations in
SBS patients without underlying Crohn’s disease [26]. In-
fections associated with intestinal failure requiring home
parenteral nutrition are mainly catheter-related [27,28].
Here we describe two individuals with short bowel
syndrome, mutations in the NOD2 gene and tuberculous
lymphadenitis. This is a clinically important finding be-
cause in a HPN patient intermittent fever, the key symp-
tom of tuberculous lymphadenitis, usually indicates
catheter related blood stream infection. To our best
knowledge, this is the first case report linking these clin-
ical entities together.Materials and methods
Genotyping of patients was performed as part of a larger
study in a cohort of short bowel patients, which was
approved by the Ethics Committee of the University of
Tuebingen (022/2011BO2). The patients gave written in-
formed consent. The three major mutations in the NOD2
gene (SNP 8; R702W, NCBI reference SNP ID: rs2066844
and SNP 12; G908R, NCBI reference SNP ID: rs2066845
and 3020insC, SNP 13; 1007 fs, NCBI reference SNP ID:
rs2066847) were detected in genomic DNA extracted from
whole blood as described previously [26].
Direct Nucleic Acid Amplification Test (NAAT) to de-
tect M. tuberculosis complex DNA was performed using
the ProbeTec ET DTB (DTB) (Becton-Dickinson). For
identification of Mycobacterium tuberculosis complex
species GenoType® MTBC (Hain) was used according to
manufacturer’s instructions. As gold standard culture
techniques using 2 solid and BACTEC™ MGIT™ 960 liquid
broth were applied. For direct susceptibility testing we used
the BACTEC™ MGIT™ 960. As interferon-gamma-release
assay we used the QuantiFERON-TB® Gold In-Tube test
(Cellestis) according to manufacturer’s instructions.Case presentation
Patient 1
Patient 1 is a 44 year-old Caucasian woman with intes-
tinal failure. In 2008, she required surgical resection ofmost of her small intestine (except for 70 cm of prox-
imal jejunum) and the right colon resulting in a duo-
denotransversostomy due to acute occlusion of her
superior mesenteric artery. Total parenteral nutrition
was initiated at the University of Tübingen intestinal
failure outpatient clinic. The initial clinical course was
dominated by numerous infectious complications, e.g.
recurrent line infections (05/2009, 04/2010, 02/2012), a
liver abscess and an episode of acute cholecystitis in the
absence of cholelithiasis, which was interpreted as an-
other ischemic episode in the splanchnic circulation
(Figure 1).
Despite an extensive workup (including ultrasound and
CT-scan) the etiology of the ischemic events could not be
determined. The diagnosis of Takayasu Arteriitis was enter-
tained because of diminished/absent peripheral pulses but
vasculitis was neither found by histology in the resected
specimens nor by PET-CT in the large vessels. Workup for
a coagulation disorder revealed a heterozygous prothrom-
bin mutation (G20210A). An antiphospholipid syndrome
was ruled out and the JAK2-mutation was also not de-
tected. A HIV test was negative.
Because of the severity of two acute episodes of arter-
ial occlusion the patient was maintained on low dose
steroids (Prednisolone 5 mg) and received long term
anticoagulation with enoxaparin (Clexane) and later fon-
daparinux (Arixtra). Under this regimen, the patient did
not develop another episode of intestinal or systemic ar-
terial ischemia.
Genetically she was found to be heterozygous for the
1007 fs NOD2 mutation. In 2010, after two years of suc-
cessful parenteral nutrition without any infectious com-
plications the patient started to lose weight and had
intermittent episodes of fever. The laboratory values
showed an increased CRP value (30.5 mg/dl) and anemia
(6.7 g/dl). A catheter-related infection was excluded by re-
peated blood cultures. Another FDG-PET-CT was ob-
tained addressing again the question of a large vessel
vasculitis. Unexpectedly it showed for the first time an in-
tensive uptake of the FDG tracer in three lymph nodes in
the mediastinum. An interferon-γ-release assay was posi-
tive (Quantiferon®). A transbronchial biopsy of one of the
lymph nodes revealed necrotic material and a granuloma
by histology, highly suggestive for tuberculous lympha-
denitis. M. tuberculosis-DNA was detected by PCR and
cultures obtained from the lymph node also grew M. tu-
berculosis. Intravenous tuberculostatic therapy with Eth-
ambutol, Isoniazid and Rifampicin was given for 4 months
followed by Isoniazid and Rifampicin for another
8 months. The follow-up FDG-PET-CT after 7 months of
therapy showed a significant size reduction and decreased
FDG uptake of the lymph nodes in the mediastinum. The
patient stayed on prophylactic therapy with Isoniazid until
today, because she continued low dose steroids.
Figure 1 Patient 1. Upper row - before tuberculostatic therapy: High FDG uptake in an infracarinal lymph node (left panel: fusion images of PET/
CT) correlating with central necrosis in the contrast enhanced CT (middle panel). Coronal MIP with high FDG uptake in several mediastinal lymph
nodes (right panel). Lower row - 8 month follow up: No FDG uptake (left panel: PET/CT) and significant size reduction of the visualized lymph
nodes (middle panel: ceCT). No pathological FDG uptake in the mediastinal lymph nodes on coronal MIP of PET (right panel).
Figure 2 Patient 2. Upper row - before tuberculostatic therapy:
high FDG uptake in several mediastinal and one right axillary (arrow)
lymph nodes. Additionally, further lymph nodes with high FDG uptake,
especially in the left paraaortal (arrow head) region. Lower row - 7 month
follow up after initiation of tuberculostatic therapy: No FDG uptake in the
right axillary lymph nodes and significant regression of FDG uptake of
the paraaortal lymph nodes after therapy. All PET positive lymph nodes
had a morphological correlate and showed a significant size reduction
after therapy in contrast enhanced CT (not shown).
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Patient 2 is a 77 year-old Caucasian woman who had an
infarction of the small intestine and right colon due to
atherosclerotic occlusion of the superior mesenteric artery
in November 2003. She required extensive resection of
her small bowel, which resulted in a jejunotransversost-
omy with 20 cm of proximal jejunum. Total parenteral nu-
trition was started and was managed at the University of
Tübingen intestinal failure outpatient clinic. In 2010 she
developed fever, weight loss and night sweats. An elevated
ESR and LDH were found. Repeated attempts to verify
catheter related blood stream infection including numer-
ous blood cultures, several rounds of empiric antibiotic
therapy and an empiric exchange of the catheter had no
sustained effect on these symptoms. A FDG-PET-CT scan
was performed addressing a potential infectious focus
other than the catheter. Unexpectedly it revealed PET-
positive lymphadenopathy in the cervical region and in
the mediastinum. An interferon-γ-release assay was nega-
tive (Quantiferon®). A bronchoscopic biopsy of the suspi-
cious lymph node revealed granulomatous necrotizing
lymphadenitis, but acid fast bacilli could not be stained. A
specific pathogen could not be cultured and eubacter-
ial PCR as well as PCR for M. tuberculosis were nega-
tive. The family history revealed that several relatives
had suffered from tuberculosis. Based on the sum of
indirect evidence the diagnosis of tuberculous lymph-
adenitis was made. Tuberculostatic therapy (Isoniazid,
Rifampicin, Ethambutol and Levofloxacin) was applied
intravenously for 6 months. The patient soon felt bet-
ter and gained weight. Fever and anemia resolved, and
the LDH and the ESR returned to normal values.Regression of the enlarged and hypermetabolic lymph
nodes was verified by another PET-CT-scan obtained
7 months after the initiation of specific therapy. One
remaining small mediastinal lymph node was regarded
as non-specific, (Figure 2).
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R702W mutation in the NOD2 gene.
Conclusion
In patients with intestinal failure on HPN the occur-
rence of low grade fewer, night sweats, declining per-
formance status, low albumin and sometimes increased
bilirubin usually prompts the diagnosis of a line related
infection. This is because about 30% of line related infec-
tions in this cohort do not present with typical symp-
toms of high grade fever and rigors upon start of a new
infusion but rather with those atypical symptoms [28].
In addition line related infections are the most frequent
complication in HPN patients occurring with a fre-
quency between two episodes per year and one episode
every three years [28]. Nevertheless the diagnosis of line
related infection could not be firmly established in either
of these patients and empiric therapy was not successful.
Instead tuberculous lymphadenitis was diagnosed and
successfully treated. Predisposition for acquiring or re-
activating tuberculosis may have been facilitated by the
fact that patients with SBS receiving long term HPN
have an impaired immune response [29]. Furthermore
patient 1 was receiving steroids over a prolonged period
of time system. It must also be noted that patient 2 may
have had an atypical mycobacterial infection. On the
other hand, tuberculosis, especially tuberculous lymph-
adenitis, has not been recognized as a specific problem
in intestinal failure patients on HPN yet. So how may
these conditions be related other than by chance?
Both patients carried a mutation in the NOD2 gene
(patient 1: 1007 fs, patient 2: R702W). NOD2 is an intra-
cellular pattern recognition receptor which recognizes
muramyl dipeptide (MDP) as part of peptidoglycan of
the bacterial cell wall [30,31]. The cumulative incidence
(homozygous, heterozygous and compound heterozy-
gous) of mutations in the 3 major NOD2 SNPs (R702W,
G908R and 1007 fs) is 13.6% in a cohort of healthy con-
trols [7]. Recently we and others have reported an in-
creased frequency of NOD2 mutations in SBS patients
[26,32]. At present it is not clear, whether a defect in
NOD2 signaling leads to an altered response to operative
stress ultimately resulting in a SBS or whether intestinal
adaptation to the SBS situation is diminished resulting
in long term HPN [26].
M. tuberculosis is mainly recognized via PRR like TLRs
and NOD2. Certain mutations in the TLR genes, e.g. TLR1
and TLR6 are associated with an increased risk of acquir-
ing M. tuberculosis [5,6]. In one study, host cells after ex-
posure to M. tuberculosis were sensing the microbe-
associated molecular pattern (MAMP) using independent
PRRs like NOD2 and TLR. The study showed, that these
receptors were non-redundant and interacted with each
other synergistically [33]. In addition monocytes frompatients homozygous for the 1007 fs mutation (3020insC)
show diminished TNF and IL-10 cytokine response after
stimulation with M. tuberculosis compared to heterozy-
gous or homozygous wild-type controls. A cohort study in
377 African Americans with tuberculosis found that cer-
tain SNPs in the NOD2 gene were associated with either
resistance or susceptibility to tuberculosis [34]. Neverthe-
less NOD2 mutations have not been firmly established as a
risk factor for tuberculosis and several studies argue
against such a correlation [35,36].
Thus, NOD2 mutations may be the common risk fac-
tor for both patients to develop intestinal failure requir-
ing HPN and to acquire or reactivate tuberculosis, in
these two cases tuberculous lymphadenitis. From a clin-
ical point of view these two cases highlight the import-
ance to search for alternative infectious complications
other than line related blood stream infection in patients
with SBS on HPN, including tuberculosis.Consent
Written informed consent was obtained from both pa-
tients for publication of this Case report and any accom-
panying images. A copy of the written consent from
both patients is available for review by the Editor of this
journal.
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